[Antiphospholipid antibodies in HELLP syndrome: clinical and biological study in 68 women]

V Queyrel1, A-S Ducloy-Bouthors, U Michon-Pasturel

  • 1Service de médecine interne, hôpital Claude-Huriez, CHRU de Lille, rue Polonovski, 59037 cedex, Lille, France. v-queyrel@chru-lille.fr <v-queyrel@chru-lille.fr>

La Revue De Medecine Interne
|March 27, 2003
PubMed

Insights

HELLP syndrome, a serious pregnancy complication, may indicate antiphospholipid syndrome. This study investigated anticardiolipin antibodies in HELLP syndrome patients, revealing a potential link between the two conditions.

Area of Science:

  • Obstetrics and Gynecology
  • Immunology
  • Hematology

Context:

  • HELLP syndrome (Hemolysis, Elevated Liver enzymes, and Low Platelets) is a severe pregnancy complication.
  • Antiphospholipid syndrome (APS) is an autoimmune disorder associated with an increased risk of thrombosis and pregnancy morbidity.
  • The co-occurrence of HELLP syndrome and APS is rare, with limited reported cases.

Purpose:

  • To investigate the prevalence of anticardiolipin antibodies (aCL) in pregnant women diagnosed with HELLP syndrome.
  • To determine if HELLP syndrome can be a presenting manifestation of antiphospholipid syndrome.
  • To assess the persistence of aCL in patients following HELLP syndrome.

Summary:

  • Anticardiolipin antibodies were detected in 9 out of 68 (13.2%) women with HELLP syndrome.
  • The incidence of aCL in HELLP syndrome was 42.8 per 1000 HELLP years.
  • Antiphospholipid syndrome was diagnosed in 2 patients, with a prevalence of 0.03% during the study period.

Impact:

  • HELLP syndrome may serve as an indicator for underlying antiphospholipid syndrome.
  • Early identification of aCL in HELLP syndrome patients could lead to timely APS diagnosis and management.
  • This finding highlights the importance of considering autoimmune etiologies in severe obstetric syndromes.
Abstract